Summit Therapeutics PLC Company Profile (NASDAQ:SMMT)

Analyst Ratings

Consensus Ratings for Summit Therapeutics PLC (NASDAQ:SMMT) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.33 (204.76% upside)

Analysts' Ratings History for Summit Therapeutics PLC (NASDAQ:SMMT)
Show:
DateFirmActionRatingPrice TargetActions
6/21/2016Janney Montgomery ScottInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2016Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/2/2015Needham & Company LLCReiterated RatingBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2015JMP SecuritiesInitiated CoverageOutperform$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Summit Therapeutics PLC (NASDAQ:SMMT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/27/2015Q215($0.06)($0.55)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
6/11/2015Q115($0.06)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Summit Therapeutics PLC (NASDAQ:SMMT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.78)($0.78)($0.78)
Q3 20171($0.64)($0.64)($0.64)
Q4 20171($0.71)($0.71)($0.71)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Summit Therapeutics PLC (NASDAQ:SMMT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Summit Therapeutics PLC (NASDAQ:SMMT)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Summit Therapeutics PLC (NASDAQ:SMMT)
DateHeadline
07/26/16 06:53 PMNew Broker Ratings For Summit Therapeutics Plc (SMMT) - FTSE News
07/22/16 06:16 PMWere Analysts Bullish Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) This Week? - Consumer Eagle
07/19/16 07:12 AMSummit Therapeutics plc : Result of AGM - PharmiWeb.com (press release)
07/18/16 11:50 AMSummit Therapeutics plc : Result of AGM
07/15/16 11:43 AMSummit Therapeutics Plc (SMMT) Updated Price Targets - FTSE News
07/13/16 09:21 AMHow Analysts Rated Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) Last Week? - Consumer Eagle
07/11/16 11:05 AMBullish Chart Formation for Summit Therapeutics PLC (ADR) After Forming Inverse H&S Chart Pattern - Press Telegraph
07/11/16 11:05 AMNext Weeks Broker Price Targets For Summit Therapeutics Plc (SMMT) - Fiscal Standard
07/06/16 11:06 AMBroker Outlook For The Week Ahead Summit Therapeutics Plc (SMMT) - Fiscal Standard
07/02/16 09:05 AMUK car production up in May, but stability vital, says SMMT - Plastics & Rubber Weekly
07/01/16 06:29 PMSingle market boosts UK car industry
07/01/16 06:29 PMBrexit vote to lead to 'instability' in the car industry
07/01/16 06:29 PMSingle market boosts United Kingdom auto industry, says SMMT
07/01/16 06:29 PMUK car output rises 26% in May, but industry group sees Brexit threat
07/01/16 06:29 PMUK automotive reports record £71.6 billion turnover
07/01/16 06:29 PMU.K. Auto Industry’s 2015 Growth Robust, Report Says
07/01/16 06:29 PMUK car production up in May, but stability vital, says SMMT
07/01/16 06:29 PMRAY MASSEY: Manufacturers plough billions into electric driving with all new cars and vans set to be mains powered by 2040
06/30/16 06:42 PMJanney Montgomery Scott Initiates Coverage on Summit Therapeutics PLC (ADR) to Buy - Trade Calls
06/28/16 11:14 AMSummit Therapeutics plc : Exercise of Options
06/25/16 10:07 AMRecently Issued Stock Ratings For Summit Therapeutics Plc (SMMT) - Fiscal Standard
06/24/16 09:00 AMSummit Therapeutics plc : Award of Options
06/23/16 07:08 PMSummit Therapeutics PLC (NASDAQ:SMMT) price target held steady to $0 as issued in a report today by Janney Capital - Breaking Finance News
06/22/16 06:25 PMSummit uses more than gut instinct to prove C.diff antibiotic's worth
06/22/16 06:25 PMSummit Therapeutics PLC (NASDAQ:SMMT) price target held steady to $0 as issued in a report today by Janney Capital
06/21/16 01:40 PMSummit Therapeutics PLC (ADR) (SMMT) Is Hot On Sarepta Therapeutics Inc (SRPT)’s DMD Tail -
06/21/16 10:46 AMSummit Therapeutics PLC (ADR) (NASDAQ:SMMT) Is Hot On Sarepta Therapeutics Inc (NASDAQ:SRPT)'s DMD Tail - Market Exclusive
06/20/16 11:49 AMSummit’s Ridinilazole Preserves Microbiome During Treatment of C. Difficile Infection - [at noodls] - Summit Corporation plc Summit Therapeutics plc ("Summit" or the "Company") SUMMIT'S RIDINILAZOLE PRESERVES MICROBIOME DURING TREATMENT OF DIFFICILE INFECTION Microbiome-Sparing Action ...
06/18/16 05:35 PMSummit Therapeutics : First Patient Enrolled in Summits PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys With DMD
06/18/16 10:32 AMAyretrade, Inc. (SUMM) Announces Enrollment of First Patient in PhaseOut DMD
06/17/16 06:11 PMSummit Therapeutics plc : Notice of AGM
06/17/16 09:07 AMSummit Therapeutics recruits first DMD phase II trial patient
06/17/16 07:19 AMFirst Patient Enrolled in Summit’s PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys with DMD - [at noodls] - 7e88d7fb-3ed3-48cd-ac6e-24bef220f55c.pdf Summit Therapeutics plc ("Summit" or "the Company") FIRST PATIENT ENROLLED IN SUMMIT'S PhaseOut DMD, A PHASE 2 CLINICAL TRIAL OF EZUTROMID IN ...
06/16/16 07:39 AMSummit to Present at JMP Securities Life Sciences Conference - [at noodls] - f2d91ddf-358f-4c6d-9111-841417a3ad7d.pdf Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO PRESENT AT JMP SECURITIES LIFE SCIENCES CONFERENCE Oxford, UK, 16 ...
06/13/16 09:26 AMSmall British Companies Are Less Wary of an Exit From EU
06/08/16 09:33 AMSummit Therapeutics to host New York DMD event
06/08/16 09:18 AMSummit Therapeutics to Host Utrophin R&D Day 15 June 2016 - [at noodls] - d9fc8eaf-b157-4dac-87a8-292d9f74dd81.pdf Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO HOST UTROPHIN R&D DAY 15 JUNE 2016 Oxford, UK, 8 June 2016 - Summit ...
06/07/16 09:15 AMSarepta surges on new hopes for its DMD drug
06/03/16 09:27 AMSummit Therapeutics Plc (SMMT) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News
06/02/16 06:57 PMSummit set to start dosing in DMD trial in second quarter - Proactive Investors USA & Canada - Proactive Investors USA & CanadaSummit set to start dosing in DMD trial in second quarterProactive Investors USA & CanadaMuscle data from a Phase 2 clinical trial for its Duchenne muscular dystrophy (DMD) treatment Ezutromid is expected in January 2017, drug developer Summit Therapeutics PLC (NASDAQ:SMMT, LON:SUMM) revealed today. It expects to start enrolling and ...Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2016 and Operational ProgressGlobeNewswire (press release)all 2 news articles »
06/02/16 12:55 PMFinancial Results from the First Quarter Ended 30 April 2016 - [at noodls] - Summit Corporation plc Summit Therapeutics plc‌‌‌‌‌‌ ("Summit" or the "Company") SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30 APRIL 2016 AND OPERATIONAL ...
06/02/16 09:39 AMSummit Therapeutics plc : 1st Quarter Results - Oxford, UK, 2 June 2016 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and C. difficile infection ('CDI'), today reports its financial results for ...
06/02/16 09:39 AMSummit set to start dosing in DMD trial in second quarter - Muscle data from a Phase 2 clinical trial for its Duchenne muscular dystrophy (DMD) treatment Ezutromid is expected in January 2017, drug developer Summit Therapeutics PLC (NASDAQ:SMMT, LON:SUMM) revealed today. It expects to start enrolling and dosing ...
06/02/16 06:00 AMSummit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2016 and Operational Progress - [GlobeNewswire] - OXFORD, United Kingdom, June 02, 2016-- Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, today reports ...
06/01/16 10:43 AMSummit Therapeutics Plc :SMMT-US: Earnings Analysis: Q4, 2016 By the Numbers : June 1, 2016 -
06/01/16 09:26 AMSummit Therapeutics plc (NASDAQ:SMMT) To Release Earnings On Thursday - Share Trading News - Summit Therapeutics plc (NASDAQ:SMMT) To Release Earnings On ThursdayShare Trading NewsThese holdings make up 5.27% of the company's outstanding shares. The stock increased 2.63% or $0.22 during the last trading session, hitting $8.65. Summit Therapeutics plc (NASDAQ:SMMT) has fallen 17.8% over the past 6 months and is downtrending.
05/31/16 06:00 AMSummit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2016 on 2 June 2016 - [GlobeNewswire] - OXFORD, United Kingdom, May 31, 2016-- Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting ...
05/30/16 09:03 PMNext Weeks Broker Price Targets For Summit Therapeutics Plc (SMMT) - Share Trading News - Next Weeks Broker Price Targets For Summit Therapeutics Plc (SMMT)Share Trading NewsSummit Therapeutics plc has a 50 day moving average of 8.20 and a 200 day moving average of 8.67. The stock's market capitalization is 103.02M, it has a 52-week low of 4.26 and a 52-week high of 13.30. The share price of the company (SMMT) was up ...and more »
05/26/16 12:43 PMSummit Therapeutics to present CDI antibiotic results - Drug discovery and development company Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT) will present positive phase II trial data on its Clostridium difficile infection (CDI) drug at the ASM Microbe 2016 meeting in Boston next month. The group’s ...
04/26/16 06:00 AMSummit’s IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid (SMT C1100), Into the US - [GlobeNewswire] - Enrolment of Patients with DMD in the US Expected to Start 3 Q 2016 Utrophin Modulation Offers Differentiated Approach in DMD OXFORD, United Kingdom, April 26, 2016-- Summit Therapeutics plc, the drug ...

Social

About Summit Therapeutics PLC

Summit Therapeutics PLC logoSummit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. The Company is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The Company's lead DMD product candidate is SMT C1100, an orally administered small molecule. The Company's lead CDI product candidate is SMT19969, an orally administered small molecule antibiotic. The Company subsidiaries include Summit Therapeutics, Inc., Summit (Oxford) Limited, Summit (Wales) Limited and MuOx Limited, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SMMT
  • CUSIP:
Key Metrics:
  • Previous Close: $7.00
  • 50 Day Moving Average: $7.70
  • 200 Day Moving Average: $7.87
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $85.85M
  • Beta: 0.91
  • Current Year EPS Consensus Estimate: $-0.59 EPS
  • Next Year EPS Consensus Estimate: $-2.05 EPS
Additional Links:
Summit Therapeutics PLC (NASDAQ:SMMT) Chart for Friday, July, 29, 2016